🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

T3 Pharma closes its second financing round with existing investors joined by «Boehringer Ingelheim Venture Fund» and «Reference Capital SA». Furthermore, we are delighted to welcome Claire Barton as Chief Medical Officer and to announce our clinical advisory board.

T3 Pharma in the final of the Swiss Economic Award 2021! We are proud to be able to pitch at the Swiss Economic Forum on 1/2 September in Interlaken and ultimately hope for first place. More at swisseconomic.ch/en/swiss-econo… #SEFAward21 #SEF21

T3 Pharma has been awarded the SEF award 2021 in the category High-tech/Biotech!!! We are extremely proud to have been selected by the jury for such prestigious price. #SEF21 #SEFaward21

🇨🇭 🚀 Swiss Accelerator: Innosuisse supports 53 innovation projects by SMEs and start-ups with significant innovation potential! Innosuisse launched the Swiss Accelerator as a transitional measure for Horizon Europe. More facts & figures: innosuisse.ch/inno/en/home/m…

Happy to share that we have received funding by the Swiss Accelerator. We are honored and extremely proud to be among these highly innovative companies! Thank you Innosuisse for trusting in T3 Pharma's team and our bacterial cancer therapy platform. innosuisse.ch/inno/en/home/m…

#NEWS: We are acquiring T3 Pharmaceuticals aiming to cure cancers and transform lives through science. Learn more about how we will realize the full potential of this novel cancer therapy platform: bit.ly/47BJHjm #ResearchCollaboration #ImmunoOncology #Cancer